Dr Duncan Jenkins on ‘Outcome-based contracts for medicines’ this month in Pf Magazine.
In this month’s issue of the Pharmafield Magazine, Dr Duncan Jenkins, Director of MORPh Consultancy Ltd, explores the financial feasibility of long- term contract incentives linked to population outcomes. This following from his article in the February issue, where he explored how partnerships based on outcome-focussed commercial arrangements might develop.
Within this topic, Dr Duncan Jenkins explains the developing frameworks for financial incentives and the deal-flow from main contractors to subcontractors. With incentives offered to manufacturers for a broad range of outcomes from population life expectancy to patient reported outcomes, lifestyle metrics, social car and performance, will the Integrated Care System be able and willing to pay these incentives to one stake holder to achieve an impact on one outcome?
Dr Duncan Jenkins then goes on to discuss whether there is sufficient margin for the pharma supplier to merit the allocation of meaningful resources to the quality improvement process by which care is refined and outcomes optimised and whether a financial risk associated with the failure to improve outcomes is prohibitive to pharma involvement.
Want to read more about Outcome-based contracts for medicine? Find Dr Duncan Jenkins’ new two-page article is available now in the March Edition of Pharmafield Magazine.
Dr Duncan Jenkins has played a vital part in judging at the Pf Awards, which will take place on the 8th March 2018 at The Lancaster Hotel, London. We wish all candidates the very best of luck from everyone here at MORPh Consultancy Ltd.
To find out more about MORPh Consultancy Ltd and how we can help with Medical Consultancy and Training, please visit us at www.morphconsultancy.co.uk or call us today on 01905612789.
